Bloom Burton Has Negative Outlook for TSE:MDP Q4 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Bloom Burton reduced their Q4 2025 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Bloom Burton analyst D. Martin now expects that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other research firms have also recently commented on MDP. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Stifel Nicolaus upped their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a buy rating and five have given a strong buy rating to the stock. According to data from MarketBeat.com, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Trading Up 10.1 %

Shares of MDP opened at C$4.92 on Friday. The stock’s 50 day moving average is C$3.25 and its two-hundred day moving average is C$2.72. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The firm has a market capitalization of C$120.69 million, a PE ratio of 98.40 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.